uniQure acquires cardiology gene therapy firm InoCard

Netherlands-based human gene therapy firm uniQure (Nasdaq: QURE) says it has acquired Germany’s InoCard GmbH, an innovative, early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.

InoCard has developed a novel gene therapy to preclinical proof of concept, for the one-time treatment of congestive heart failure (CHF), a rapidly progressing disease affecting 26 million people worldwide. InoCard founders Professors Patrick Most and Hugo Katus will join uniQure as managing director of uniQure in Germany and chairman of the scientific advisory board, for cardiovascular diseases, respectively.

Paying 3 million euros in cash and stock